武汉禾元生物科技股份有限公司董事长兼总经理杨代常先生致辞

Core Viewpoint - He Yuan Bio aims to provide green, safe, accessible, and sufficient biopharmaceutical products globally, addressing the challenge of relying on imported human serum albumin due to domestic plasma supply limitations [2][3] Group 1: Company Overview - He Yuan Bio has developed a leading plant bioreactor technology platform, achieving a breakthrough in human albumin expression levels of 20-30g/kg of brown rice [2] - The core product, OsrHSA, received approval from the National Medical Products Administration in July, marking the end of reliance on plasma extraction for human albumin and eliminating risks of human-derived pathogen transmission [2][3] Group 2: Production and Growth Strategy - The company has established a complete industrialization system covering pharmaceuticals, pharmaceutical excipients, and research reagents, completing the transition from technical breakthroughs to industrial implementation [3] - He Yuan Bio has built a cGMP intelligent production line with an annual capacity of 10 tons of OsrHSA raw solution and formulations, with a 120-ton raw solution production line under construction, set to enhance market competitiveness [3] Group 3: Future Outlook - The upcoming IPO is seen as a strategic leap in He Yuan Bio's development, leveraging the advantages of the rice endosperm cell expression platform to enhance operational management and project construction efficiency [3] - The company aims to create a world-class biopharmaceutical firm centered on recombinant protein drugs, continuously enhancing its core competitiveness and industry influence [3]